CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.

  title={CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.},
  author={Tom van Meerten and Anton Hagenbeek},
  journal={The Netherlands journal of medicine},
  volume={67 7},
Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse of the original disease. A better understanding of the mechanism of rituximab resistance has lead to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 16 extracted citations

Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells

Journal of experimental & clinical cancer research : CR • 2010
View 3 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 139 references

circulatory dynamics in B cell immunotherapy

Y Vugmeyster, J Beyer, K Howell
J Immunol • 2005
View 5 Excerpts
Highly Influenced

[Properties and structure of fibrous resins].

Deutsche zahnarztliche Zeitschrift • 1954
View 6 Excerpts
Highly Influenced

radioimmuno therapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapy

SA, CH Chan, S James
View 3 Excerpts
Highly Influenced

rituximab on primary non-Hodgkin lymphomas

JC Byrd, S Kitada, IW Flinn
View 7 Excerpts
Highly Influenced

anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

WK Weng, R. Levy
View 5 Excerpts
Highly Influenced

by a chimeric mouse human monoclonal antibody to CD20

HT Chan, D Hughes, RR French
View 4 Excerpts
Highly Influenced

Ofatumumab: a novel monoclonal anti-CD20 antibody

Pharmacogenomics and personalized medicine • 2010
View 2 Excerpts

Indolent Lymphoma: Where Do We Stand? (Editorial) J Clin Oncol

H Hochster, E Weller, RD Gascoyne
View 1 Excerpt

Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009

Similar Papers

Loading similar papers…